Special Authority Criteria - Prasugrel
As of January 31, 2020, the manufacturer of prasugrel (Effient®), Eli Lilly Canada, discontinued its Canadian supply of the drug. Commercially available Canadian supply (stock on shelves and wholesalers) with patients that have previous approved active Special Authority can continue to have coverage until stock is depleted.
Practitioners have been informed of the short supply and advised to not start any new patients on Effient. In some cases where it is medically necessary for a patient to remain on the drug, the prescriber may apply to Health Canada’s Special Access Programme (SAP). Eli Lilly will cover the costs of approved requests for patients to continue the drug, however, remaining stock may not last beyond February 2021.
Effective January 31, 2020, PharmaCare will no longer be providing coverage for new patients or renewals.